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To see a World in a Grain of Sand And a Heaven in a Wild Flower,  
Hold Infinity in the palm of your hand And Eternity in an hour. 
 









Assisted reproductive technology (ART) is increasingly used worldwide to treat infertility 
and assist couples and single mothers with their conception. The most common ART 
procedure includes treatment with exogenous hormones to stimulate the ovaries to produce 
multiple oocytes, followed by an in vitro fertilisation (IVF) achieved by letting oocyte and 
sperm combine in vitro or by direct intracytoplasmic sperm injection (ICSI) into the oocyte. 
After cultivation into an embryo for two to three days or five to six days into a blastocyst, a 
subsequent embryo transfer (ET) is performed, either a fresh ET or a frozen-thawed embryo 
or blastocyst transfer in a later, natural or ”programmed” cycle.  
During pregnancy the incidence of venous thromboembolism (VTE) is at least five-fold 
increased as compared to same-aged, non-pregnant women and the incidence is even further 
increased during ART pregnancies. A doubled incidence has been reported during the whole 
pregnancy, mostly accounted for in the first trimester by a four-fold increased incidence of 
overall VTE and a seven-fold increased incidence of pulmonary embolism (PE) in women 
giving birth after ART as compared to matched women with spontaneous pregnancies. Even 
though the incidence is low with 1-2 per 1,000 in spontaneous pregnancies and 3-6 per 1,000 
in ART pregnancies there has to be an awareness of the risk. VTE and PE are responsible for 
long-term morbidity, with the post-thrombotic syndrome and impaired exercise capacity after 
PE, and also an increased mortality with PE being a leading cause of maternal mortality. 
Since the highest incidence was found during the first trimester of ART pregnancies we 
hypothesised that this could be related to the hormone increase during ovarian stimulation. 
 
Aims 
The aim of this doctoral project was to achieve more knowledge of potential mechanisms 
behind the increased incidence of VTE found in ART pregnancies as compared to 
spontaneous pregnancies.  
 
Methods and results 
To gain knowledge on potential mechanisms explaining the prothrombotic state during ART, 
we analysed previously collected blood samples from 31 women undergoing ovarian 
stimulation. The samples were taken at down regulation of the ovaries, when endogenous 
oestrogen levels are almost undetectable, and during ovarian stimulation with its 10-100-fold 
increased oestrogen level. We aimed to detect changes of cell-derived plasma     
microvesicles (MVs) and found a significant increase of potentially prothrombotic MVs with 
a majority of platelet-MVs exposing markers of activation and inflammation. Further, we 
analysed alterations of the plasma MV proteome to probe quantitative and qualitative changes 
of the whole MV protein content during ovarian stimulation. We aimed to capture and 
identify potential pathophysiological mechanisms concomitant with the oestrogen surge. We 
further aimed to find potential biomarkers that could help to identify the development of a 
hypercoagulative state that could help to explain the increased VTE incidence found in ART. 
Furthermore, we performed a nationwide cohort study of all pregnancies during 20 years in 
Sweden and studied the incidence of VTE in women giving birth after a fresh ET and after a 
frozen, thawed ET performed in a later cycle. We compared these VTE incidences to that of 
women with spontaneous pregnancies. We found that the incidence of overall VTE and PE 
was more than eight-fold increased during the first trimester in the group of women with a 
fresh embryo transfer as compared to spontaneous pregnancies. We found no cases of PEs in 
the frozen ET group during the first trimester.  
 
Conclusions 
Our results could speak in favour of frozen ET over fresh ET to achieve a minimised risk of 
VTE after ART. The increase in MVs indicated a procoagulant state and platelet activation 
during the ovarian stimulation phase of ART. Larger study populations are required to 
evaluate whether the proteins identified in the MV proteome could have a potential as 
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1.1 VENOUS THROMBOEMBOLISM 
Venous thromboembolism (VTE) is the third most common cardiovascular disease after 
coronary heart disease and stroke and is caused by a combination of genetic and acquired risk 
factors. The term VTE includes deep vein thrombosis (DVT) and pulmonary embolism (PE). 
DVT most commonly occurs in the lower extremities in the valves of the calf veins, but can 
also occur at more unusual sites, such as the deep veins of the upper extremities, the 
abdominal or in rare cases even the cerebral veins. When parts of a thrombus loosen and 
travel with the circulation to another location of the vessel they are called emboli. The 
thrombi and emboli cause obstructions of blood flow. Around two thirds of all VTE manifest 
as DVTs and one third as PEs.  
PE is considered to most commonly 
originate from DVTs of the lower 
extremities, but can also have its origin in 
the other mentioned localisations, such as 
the upper extremities, renal veins, inferior 
cava vein or the right atrium of the heart, see 
figure 1. PE restrict pulmonary arterial 
circulation and cause a variety of symptoms, 
e.g. dyspnea and pleuritic chest pain. Large 
emboli to the main or central pulmonary 
arteries can cause total blockage of the 
pulmonary circulation and subsequent 
hemodynamic collapse and cardiac arrest. 
The incidence of VTE is reported to be 
around 1 per 1,000 annualy in the general 
population, while there is an increase 
with age and a difference between the 
sexes at different ages 1 2. In women  
below age 50, during the years of reproduction, the incidence of VTE is increased compared 
to men, but overall men have a higher risk than women both of first and recurrent VTE 3 4. 
Besides of age other strong risk factors for VTE are previous episodes of VTE with a 
recurrence risk exceeding 30 % within 10 years, family history and immobilisation after 
surgery 5. Around 20 % of all VTE occur in cancer patients 6. 
Figure 1. Pulmonary embolism. Picture from 
Servier Medical Art licensed under the Creative 
Commons Attribution 3.0 Unported License. 
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1.1.1 Virchow’s triad 
In the 19th century the pathologist Virchow summarised the risk factors for VTE in the three 
cornerstones still valid today and it includes the dysfunctional or damaged endothelium, 
blood components causing hypercoagulability and restriction of blood flow, venous stasis, as 
seen in figure 2 7.  




The factors are often intertwined and they interact. Endothelial damage typically occurs after 
surgery, trauma, indwelling vein catheters, delivery and in cancer. A previous VTE can cause 
a long-term dysfunctional endothelium possibly contributing to a quite substantial risk of 
recurrence. 
Venous stasis occurs when blood flow is restricted due to immobilisation after major 
ortophedic surgery in particular, hospitalisation after both surgery and medical illness, 
oedema due to heart failure or nephrotic syndrome, cancer with compression of the veins by 
tumours or during pregnancy with a growing uterus or the hormonal effect on the veins. 
Hospitalisation within three months after surgery or medical illness has been accounted for 
more than 50 % of all VTEs in an American study 6. Immobilisation during long travel flights 
exceeding six hours entails a certain risk of VTE, in particular for travellers with other VTE 
risk factors 8.  
Hypercoagulability can be related to both hereditary and acquired factors. Testing for 
hereditary thrombophilia in general include testing factor V Leiden gene mutation causing 
resistance to activated protein C (APC), the prothrombin gene mutation causing elevated 
levels of coagulation factor II and the gene mutations causing deficiency of the coagulation 
inhibitors antithrombin (AT), protein C and protein S. Thrombophilia testing has not been 
shown to reduce recurrent VTE and thus screening patients with a first event is not a routine 
in most clinics 9.  Family history alone is a strong indicator of VTE risk with a two to four-
fold increased risk of a first VTE 10. Other genetic risk factors are blood groups other than 




Endothelial damage Hypercoagulation 
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Among other than the mentioned acquired risk factors causing hypercoagulability are 
myeloproliferative disease, inflammatory disease and the antiphospholipid syndrome.  
Still many cases of VTE are idiopathic, i.e. occur without a known risk factor. If a family 
history is present or when a need for individual risk assessment is desirable, thrombophilia 
screening can be warranted, but is still debatable 12. To what extent cancer screening should 
be performed in patients experiencing a VTE without a known risk factor or symptoms is also 
debated. Studies have found an an incidence of cancer during the first two years after a first 
incident VTE 7-8 % 13 14. 
 
1.1.2 Diagnosing VTE 
When diagnosing DVT in the lower extremities or suspected PE in hemodynamically stable 
patients clinical probability scores based on symptoms and risk factors should be used. 
Depending on pre-test probability and factors contributing to the risk of a false test result 
laboratory testing can be performed with the fibrin degradation product D-dimer. If D-dimer-
testing is positive in a low- or intermediate risk patient or when the pre-test probability is 
high, diagnostic imaging will be requried. In suspected DVT of the lower extremitites duplex 
ultrasound with venography doppler and vein compression will be performed, while in 
suspected PE either a spiral computed tomography pulmonary angiography (CTPA) or a 
ventilation-perfusion (V/P) scintigraphy will be performed. Each hospital or care center 
should have an algorithm based on available methods, see figure 3. In some cases with a 
negative D-dimer a repeated duplex ultrasound has to be performed after a week, further 
diagnosing of the more proximal veins using CT angiography or MRI and a new assessment 
of other diagnoses that could cause the symptoms.  
V/P-scintigraphy can be used when PE is supected in a hemodynamically stable patient. It 
could also be warranted when radiation to the female chest should be minimised, such as in 
pregnancy, in younger patients without pulmonary disease or when the presence of renal 
disease requires caution with contrast.  
MRI could be another option in diagnosing VTE and there are ongoing studies on both PE 
and DVT. A previous study from 2010 on iliac vein thrombosis during pregnancy assessed 
duplex ultrasound and MRI in all 27 patients at pregnancy week 29 (range week 23-39) and 
in 3 women the iliac vein thromboses were detected only by MRI, thus missed diagnose with 
ultrasound 15.  Regarding recurrent DVT of the lower extremities recent studies suggest MRI 










Prediction and diagnosis of VTE is important and adequate thrombembolic prophylaxis 
should be prescribed for patients at risk. Prediction scores and local guidelines on prophylaxis 
might be helpful. This was recently realised during the outbreak of the Coronavirus disease, 
Covid-19, where critically ill patients were found to have a high incidence of VTE despite 
standard thromboprophylaxis 17. In severe Covid-19-infection markedly elevated D-dimers 
and fibrinogen levels are found indicating a hypercoagulable and hyperinflammatory state 18. 
Several local guidelines now recommend to consider increased thromboprophylaxis in 
patients with severe Covid-19 infection and there is a lot of ongoing research on the etiology 
of the prothrombotic state in Covid-19 with continuously updated guidelines, thus not 
referred herein.  
 
1.1.3 Morbidity and mortality in VTE 
VTE is indeed a rare event, but bears a substantial risk of long-term complications and 
though rare even potentially fatal consequenses 2. A Norwegian study on patients 20 years or 
older reported a case fatality rate of around 10 % for PE and 5 % for DVT with a doubled 
risk of dying from PE compared to DVT within 30 days after a first incident VTE 3. Other 
studies reported an even higher case fatality rate within the first 3-12 months after diagnose 
of VTE ranging between 11-13 % 19 20. A recently published study found a decreasing trend 
in the reported mortality rates for PE over the last 15 years in the United States with a 
mortality rate decreasing linearly from 12.8 (95 % CI 11.4-14) in 2000 compared to 6.5 per 
100,000 (95 % CI 5.3-7.7) in 2015 21. 
Suspected DVT/PE
Clinical assessment + score
Low or intermediate probability High probability
PositiveNegative Diagnostic imagingDuplex ultrasound/CTPA or V/P-scint
D-dimer
No DVT/PE
New assessment on diagnose
No DVT/PE
New assessment on diagnoseDVT/PE
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Around 20-50 % of patients experiencing a DVT will develop a post-thrombotic syndrome 
(PTS) of varying severity with long-term complications including symptoms such as 
swelling, pain and heaviness of the legs after a DVT of the lower extremities 22-25. A more 
rare complication after PE is chronic thromboembolic pulmonary hypertension (CTEPH) 26-
28. Many patients do also experience limitations in exercise capacity after PE without 
objective findings of CTEPH 29. 
 
1.1.4 Treatment of VTE 
Anticoagulant treatment of VTE today comprise novel or direct oral anticoagulants (DOACs) 
directly inhibiting thrombin or factor X, as the drugs of choice. Though in some conditions 
anti-vitamin K (AVK) is still recommended, for example in women breastfeeding or when 
repeated presence of antiphospholipid antibodies are found in patients in the antiphospholipid 
syndrome. AVK can also be considered in patients with massive VTE or VTEs at unusual 
thrombosis sites, such as cerebral veins or abdominal veins. During pregnancy subcutaneous 
injections of low molecular weight heparins (LMWH) are used instead of oral anticoagulants. 
LMWH could also be used when a bleeding risk is present or in situations when oral 
medication is not suitable or possible. 
Most patients with a DVT can be treated as outpatients with start of DOACs at diagnosis. 
Proximal, ileofemoral DVTs with major symptoms can be considered for local, catheter-
based thrombolytic treatment and thrombus removal. Regarding patients with PE, a risk 
stratification has to be performed to decide the therapeutic management. PE is a heterogenous 
condition ranging from low-risk PE with outpatient treatment using DOACs, to high-risk PE 
with hemodynamic instability or cardiogenic shock, requiring systemic thrombolytics to 
survive.  
 
1.2 ASSISTED REPRODUCTIVE TECHNOLOGY 
Assisted reproductive technology (ART) is increasingly used worldwide to facilitate 
reproduction. The term ART refers to interventions that include techniques handling egg 
(oocyte) and sperm to assist reproduction, in accordance with the glossary of the International 
committee monitoring assisted reproductive technologies (ICMART) 30. It is estimated that 
more than 9 million children have been born after ART since the first child was born after 
IVF in 1978 in England 31. In Sweden today around 4 % of all child births are conceived by 
ART 32. ART treatment offers the possibility of conceiving a child with own or donated 
oocytes and sperm for couples or single women. Around 10-15 % of all couples are 
considered having fertility problems and with the increased age of parenthood and increased 
accessibility to the technology the number of children born after ART will most likely 
continue to increase in the future.  
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The most common procedure of ART is to use follicle stimulating hormone (FSH) to 
stimulate the ovaries to produce multiple oocytes for retrieval and subsequent fertilisation, 
while gonadotropin releasing hormone (GnRH) analogues are administered to suppress and 
hinder premature ovulation. The fertilisation is performed by either mixing the oocyte and 
sperm on a plate, standard IVF, or with the sperm directly injected into the oocyte, 
intracytoplasmic sperm injection (ICSI). The embryo is then cultivated for two to three days 
or up to five to six days to achieve a blastocyst before embryo transfer (ET) or 
cryopreservation is performed. The latter is performed using improved freezing methods with 
vitrification of the embryos at the blastocyst stage 33. In many countries, such as Sweden, the 
standard recommendation of the National Board of Health and Welfare is to perform a single 
ET because of the increased pregnancy complications noted after a multiple pregnancy 34 35. 
In the last yearly report of ART in Sweden every fourth ET leads to the birth of a child 36.  
 
1.3 SEX HORMONES AND ENDOGENOUS OESTROGEN 
The sex hormones are regulated by the axis of the hypothalamus-pituitary gland and the 
gonads. The hypothalamus produces GnRH, which signals to the anterior pituitary gland to 
release the gonadotropins, FSH and luteinising hormone (LH), which in turn signals to the 
ovaries and regulates the menstrual cycle.  
The menstrual cycle starts with the bleeding, followed by the follicular phase with rising FSH 
levels with the aim to end in ovulation. Thereafter the luteal phase continues with 
proliferation of the endometrium to prepare for implantation, stimulated by progesterone 
secreted from the corpus luteum, the rest part of the follicle that has ovulated. If fertilisation 
does not occur the levels of oestradiol and progesterone decrease and induce a menstrual 
bleeding. When a woman is at fertile age, endogenous oestrogen, oestradiol E2, and oestrone 
E1, are mainly produced and secreted from the ovarian granulose cells, but also from the 
adrenal glands and in fat tissue, while oestriol E3, is produced by the placenta during 
pregnancy, see oestradiol levels in figure 4.  
In a typical menstrual cycle the E2 level is increasing during the follicular phase with the 
highest level before LH surge which leads to ovulation. After the ovulation the progesterone 
levels are at the highest as mentioned to prepare the endometrial lining of the uterus for 
implantation. In a normal menstrual cycle the peak E2 reaches levels up to 1,500 pmol/L at 
maximum just before ovulation and then drops to below 200 pmol/L during the menstrual 
period. The level at menopause is even lower and many times not detectable 37. During 
pregnancy a study on 52 women with uncomplicated pregnancies, E2 levels were measured 
with median levels 3,200 (SE±250) pmol/L, 16,000 (SE±960) pmol/L and 23,000 (SE±1,500) 
pmol/L in the third trimester of women with normal or low levels after one year with           




Figure 4. Oestradiol levels. Reprinted with permission from publisher 39. 
 
 
ART offers a possibility to study the effects of supraphysiological oestrogen levels as induced 
by ovarian stimulation and lasting up to pregnancy week 8 after a fresh ET 40. However, the 
wide range of E2 levels makes predictions and treatment effects of different E2 levels hard to 
compare 41. In our previously published data on study population in study I-II, mean E2 level 
presented with a large spread with a mean of 5,889 pmol (SD±4,723 pmol/L) at high level 
stimulation 42.  
Though, when E2 levels were divided into different categories with higher and lower levels, 
several studies have been able to correlate E2 to different outcomes. A positive correlation 
was found with E2 levels above 4,000 pg/mL, (corresponding to 15,000 pmol/L) at the day of 
hCG-administration, and pregnancy rate in women undergoing ART with ovarian  
stimulation 43. In line with these findings another study found that low E2 levels early in ART 
pregnancies was associated with poorer pregnancy outcome 44. High E2 levels are considered 
markers of OHSS risk, although the wide spread makes risk prediction difficult. A mean 
value of >3,500 pg/mL (corresponding to about 13,000 pmol/L) in OHSS without specifying 
severity grade, was found in a majority of studies according to a review by the American 
society for reproductive medicine 45.   
There are various studies on endogenous oestrogens and risk of VTE. The hypothesis is that 
the longer the endogenous oestrogen exposure the higher the risk for VTE. In 
postmenopausal women oestrogen exposure was studied and exposure time defined by age at 
menopause and parity and they found that late menopause and multiparity was associated 
with an increased risk of VTE 46. Women undergoing ART with ovarian stimulation are 
exposed to high levels of endogenous oestrogen and with a subsequent pregnancy with its 
high oestrogen levels a hypercoagulative state might be even more prominent. A Swedish 
study on ART and ovarian cancer or borderline ovarian tumours found an increased incidence 























conceived women 47. Lifetime effect of ART on VTE incidence will have to be further 
studied in the future. 
Exogenous oestrogens in combined oral contraception (COC) and in hormone replacement 
therapy (HRT) are associated with an increased risk of VTE 48. Even in men with oestrogen 
treatment for prostate cancer an increased risk of VTE was found 49. The VTE incidence in 
women using COC is three to six-fold increased in different studies and do also depend on 
which progesteron is used, administration route and oestrogen dose 50. The incidence was 
increased by increased oestrogen dose 51 and depended on administration route, where oral 
oestrogens entailed a higher risk than transdermal 52. The possible explanation is that the first 
pass hepatic metabolism induces effects in the liver that is a producer of most of the 
coagulation factors. Postmenopausal women with HRT have a three-fold increased risk of 
VTE found in the American study, The heart and estrogen/progestin replacement study 53. It 
has been found that oestrogen has an immediate effect on haemostasis towards a 
hypercoagulable state as shown in a study of haemostatic factors measured 2-48 hours after 
intake of emergency contraceptive pill 54.  
 
1.4 HORMONE PROTOCOLS IN OVARIAN STIMULATION  
In ART ovarian stimulation with the gonadotropin FSH is used in order to achieve multiple 
follicles and oocytes for the fertilisation. FSH is given for about 10-14 days with monitoring 
of ovaries and uterus by ultrasound controls and sometimes oestradiol levels to assess 
follicular size, to adjust FSH dose and to decide on the timing of hCG to trigger the final 
oocyte maturation before oocyte retrieval.  
In Sweden a shift from long agonist to short antagonist protocols took place in the beginning 
of the millennium and today mostly short protocols are used, see figure 5. This is due to the 
combined reason of a shorter treatment duration with a less amount of exogenous hormones 
and at a lower cost, see figure 5. The long agonist protocols have been associated with more 
oocytes retrieved and a higher pregnancy rate, but are also considered to increase the risk of 
ovarian hyperstimulation syndrome (OHSS) described below 55. The shorter treatment 
protocols start with direct stimulation during the first day or days of the menstrual cycle with 
FSH, followed by a GnRH-antagonist after a few days to suppress ovulation. In these 
protocols a GnRH-agonist could be given instead of hCG to induce ovulation for example in 
women at risk for OHSS.  
In the long protocol a GnRH agonist is started around day 21 of the menstrual cycle to down 
regulate the pituitary gland and the oestrogen level and to prevent the LH surge. After 10-14 
days after a menstrual bleed or when the oestrogen level confirms DR, ovarian stimulation is 
started with FSH for around eight to ten days. Thereafter, human chorionic gonadotropin 
(hCG) is used to induce the final oocyte maturation. It acts similarly to the luteinising 
hormone (LH), but is a slower trigger so that oocyte retrieval can be scheduled after 36 hours. 
The GnRH agonist normally induces a short, initial raise in pituitary gonadotropins and 
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oestradiol level, but soon the pituitary is suppressed and hormone levels down regulated, 
followed by a drop in oestradiol and often a menstrual bleeding.  
Figure 5. The hormones used in the long agonist protocol starting day 21 of the menstrual 
cycle and the short antagonist protocol starting in the first days of the menstrual cycle.  
 
 
Ultrasound is used to monitor follicular development, often repeatedly in all protocols and 
treatment is individualised and monitored for dose adjusting and early signs of OHSS. When 
two to three follicles have reached the size over at least 16-18 mm and oestradiol levels, when 
measured indicate enough follicles, the hCG (or GnRH-agonist) can be administered for final 
maturation and oocyte retrieval. Oestradiol levels measure, as a role of thumb, around 700-
1,000 pmol/L per follicle, and thus with 10 mature follicles the E2-levels would be measured 
to be at a desired level of around 10,000 pmol/L. 
Progesterone is started after oocyte retrieval and continued until the pregnancy test, and is 
often administered vaginally.  
 
1.5 FRESH EMBRYO TRANSFER 
When an embryo is transferred to the uterus directly following ovarian stimulation and 
embryo cultivation, it is here referred to as a fresh ET. The remaining embryos are in the 
majority subjected to freezing strategies using vitrification during the freezing procedure. In 
most ART treatments a fresh ET will first be performed and thus, still more than half of all 
ETs are fresh ETs in most European countries, including Sweden 31. If a woman develops 
OHSS or is at risk to develop OHSS a freeze-all embryos strategy should be used. 
Randomised clinical trials have shown similar or even higher pregnancy rates in frozen as 
compared to fresh ET 56 57.  
 
1.6 FROZEN EMBRYO TRANSFER 
When a frozen embryo is thawed and transferred to the uterus this is called a frozen-thawed 
ET or shortly, a frozen ET. The frozen ET can either be performed in a natural cycle, if the 
Ovarian stimulation (FSH)
hCG










woman has a regular menstrual cycle, or in an artificial menstrual cycle as induced by an 
equivalent regimen to that in HRT, mostly using low doses of exogenous oestrogen and 
subsequent progesterone administration after ultrasound control of endometrial thickness.  
The timing of frozen ET is determined by measurement of LH in the woman’s urine and 
when the LH-surge is detected and ultrasound confirms ovulation, the timing of the ET is 
determined. The timing is dependent on how many days that the embryo will be cultivated to 
match embryo age with the days after ovulation. The timing of the frozen ET can as 
mentioned also be regulated by hormone treatment, i.e. a “programmed” cycle. 
 
1.7 OVARIAN HYPERSTIMULATION SYNDROME 
OHSS occurs in moderate form in a few percent of all ovarian stimulation cycles and mostly 
early after hCG administration, but can also occur later in a subsequent pregnancy when 
endogenous hCG is released from the placenta. Mild forms of OHSS are probably 
underestimated and are presumed to occur in around 20-30 % of all treatment cycles, while 
moderate to severe form has been reported in 2-6 % of cycles 58 59. OHSS is a syndrome with 
cystic enlargement of the ovaries and a leakage of fluid to the abdominal space around the 
ovaries due to increased vascular permeability. This peritoneal fluid causes abdominal pain, 
nausea and vomiting.  
OHSS has been associated with a risk of both arterial and venous thromboembolism with 
reports of a remarkably high risk of VTE as compared to that in spontaneous pregnancy 60. 
The pathophysiological mechanisms behind OHSS are still unclear, but the vascular 
permeability is engaging the endothelium. Some of the risk factors for OHSS are the 
polycystic ovary syndrome (PCOS), young age, low weight, previous OHSS, a history of 
elevated response to gonadotropins and multiple follicles retrieved (>15) 61 62.  
 
1.8 VENOUS THROMBOEMBOLISM IN PREGNANCY 
Pregnancy is a risk factor for VTE. During pregnancy and postpartum all cornerstones of 
Virchow’s triad are active. The growing uterus causes mechanical compression of the iliac 
veins and inferior vena cava in the so called May-Thurner phenomena or iliac vein 
compression syndrome, where the right iliac artery or the ovarian artery crosses the left iliac 
vein and causes local disturbance. Furthermore, the hormonal changes during pregnancy with 
progesterone affect the veins with decreased vascular tone and dilatation of veins with stasis 
of the blood flow that might contribute to endothelial dysfunction and development of DVT 
in locations with decreased blood flow 63. 
The incidence of VTE during pregnancy is 1-2 per 1,000 with the highest incidence in late 
pregnancy and the period after delivery, the postpartum period also called the puerpurium. 
The incidence of VTE is around five-fold higher than in non-pregnant women of the same 
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age and in the postpartum period the incidence has been reported to be 10-20-fold increased 
64-68. VTE and specifically PE is one of the leading causes of maternal mortality in the 
developed world with a mortality rate of 1 per 100,000 and the numbers in Sweden are 
consistent with these with 0.4-1 per 100,000 pregnancies 69 70.  
It is more common during pregnancy to experience a DVT in the left leg, due to the May-
Thurner phenomena described above. More proximal DVTs with iliac or iliofemoral vein 
thromboses are also more prevalent during pregnancy than in the population at general, with 
an increased risk of embolisation 71. The distribution of DVTs versus PEs in pregnancy reveal 
a higher prevalence of DVT than in the general population with 80 % DVT and 20 % PE, the 
latter including simultaneous DVTs during pregnancy 72. During pregnancy specific risk 
factors for VTE are multiple births, parity, caesarean section and preeclampsia 73. 
Decisions on clinical probability of VTE in pregnancy can be demanding and the 
consideration of diagnostic options as well. The high cardiac output during late pregnancy 
can make it hard to diagnose PE with CTPA, with a risk of false positives with pulmonary 
arterial contrast defects mistaken for PE or false negatives when peripheral emboli could be 
missed out. V/P scintigraphy can in turn be difficult to interpret. Radiation to both the foetus 
and the female chest should preferably be minimised. Therefore, a bilateral ultrasound of the 
lower extremities and iliac veins could sometimes be performed instead of pulmonary arterial 
imaging in suspected PE, given that the patient is hemodynamically stable 74. Unfortunately it 
can also be difficult to examine and visualise an isolated iliac vein thrombosis, especially in 
late pregnancy. Thus, the previously mentioned MRI-study performed in Gothenburg found 
that MRI was an option in pregnancy. New scoring systems including adjusted D-dimer 
levels are under development, but not enough validated as to date 75.  
 
1.9 VENOUS THROMBOEMBOLISM IN ASSISTED REPRODUCTIVE 
TECHNOLOGY 
A Norwegian population-based case-control study of risk factors for pregnancy-related VTE 
found that ART was a risk factor for VTE in women giving birth 76. They proceeded this 
study with a hospital-based case-control study of 559 cases of VTE during pregnancy and 
two non-pregnant controls for each case, where they also found that ART was a risk factor 
with an additive effect of multiple births 77. Previous to these studies there had been 
indications of VTEs in ART in numerous case reports and case series on ART with upper 
extremity and subclavian vein thromboses related to OHSS, with a possible publication bias 
for the unusual thrombosis sites 78 79.  
Since then population-based studies have been performed aimed to study the incidence of 
VTE after ART and table 1 shows a summary of the incidences and risk ratios or hazard 




Table 1. Studies of assisted reproductive technology and venous thromboembolism. 
 
 
Hansen et al published a study in 2012 including all ART treatments with ovarian stimulation 
and compared the incidence of VTE to that of a control group of women of the same age not 
using oral contraception, and found no difference 80. In their second study in 2014 shown in 
table 1, they analysed only the ART treatments leading to a child birth, including 18,787 
women compared to a reference group of spontaneously conceived women 81. They found an 
increased risk of VTE all over, in particular during the first trimester and in the postpartum 
period and in multiple birth. Further, they presented in 2018 a study of the VTE incidence 
during the first 12 weeks after ART with early pregnancy loss before 10 completed 
Author, year 
 
Rova et al. 
2012 
Henriksson et al. 
2013 
Hansen et al. 
2014 
Villani et al. 
2015 
Filipovic-
Pierucci et al. 
2019 













giving birth after 






giving birth after 







giving birth after 






234 women with a 
clinical pregnancy 








giving birth after 






VTE in ART, 
incidence (n) 
5.9 per 1,000 
(114) 
 
4.2 per 1,000 
(99) 
2.8 per 1,000  
(48) 
8.5 per 1,000 
(2) 






1.5 per 1,000 
(1428) 
2.5 per 1,000 
(291) 
1.2 per 1,000 
(727) 
1.8 per 1,000 
(6) 
Not reported 




95% CI 2.1-3.6 
Postpartum 
OR 1.2  
95% CI 0.6-2.0 
 
HR 1.8 
95% CI 1.4-2.2 
IRR 1.7 
95% CI 0.9-3.0 
Antepartum: 
IRR 3.0 
95% CI 2.1-4.3 
 
OR 3.9 
95% CI 0.87-15 
IRR 1.2 
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1.5 per 1,000  
(36) 
PE: 
 0.3 per 1,000  
(7) 
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0.17 per 1,000 
(160) 
0.3 per 1,000 
(38) 
PE:  
0.04 per 1,000 
(5) 
0.11 per 1,000 
(90) 
Not reported Not reported 
Risk ratio or 
similar 
OR 9.8 
95% CI 6.7-14 
HR 4.1 
95% CI 2.5-6.5 
PE: 
HR 7.0 
95% CI 2.2-22 
Single birth 
IRR 5.9 
95% CI 2.7-13 
Multiple birth 
IRR 8.0 
95% CI 2.5-25.5 
Not reported IRR 3.3 
95% CI 2.2-4.8 
(only ovarian 
stimulation) 
ART=assisted reproductive technology, VTE=venous thromboembolism, PE=pulmonary embolism, 




pregnancy weeks 82. They found a low incidence, only one case, incidence 1.3 (95 % CI 0.03-
7.49) per 10,000 pregnancies and compared to IVF with completed pregnancy 7.8 (95 % CI 
4.1-13.3) per 10,000 (RR 0.17, 95 % CI 0.02-1.3).  
Rova et al published a population-based cohort study in 2012 of 19,194 women giving birth 
after ART during a 10-year period 1999-2008 compared to a control population of women 
with spontaneous conception during the same period 60. They found an incidence of 1.7 per 
1,000 in ART with an almost 10-fold increased risk during the first trimester after ART 
compared to all other deliveries during the same period, 0.17 per 1,000 (odds ratio, OR 9.8, 
95 % CI 6.7-14). They also reported that 6-7 % of all women that were hospitalised due to 
OHSS had a 100-fold increased incidence during the first trimester after fresh ET. They 
reported no difference after frozen ET.  
In 2013, Henriksson et al published a population-based study on 23,498 women conceived 
after their first ART pregnancy, compared to 116,969 women, matched on age and calendar 
period, giving birth to their first child 83. They found a doubled incidence of VTE, 4.2 per 
1,000 in women conceived by ART respectively 2.5 per 1,000 in women naturally conceived 
(hazard ratio, HR 1.8, 95 % CI 1.4-2.2). The incidence was in particular increased during the 
first trimester with a seven-fold increased incidence of PE 3.0 per 1,000 versus 0.4 per 1,000 
(HR 7.0, 95 % CI 2.2-22) and for first trimester VTE 1.5 per 1,000 versus 0.3 per 1,000 (HR 
4.1, 95 % CI 2.5-6.5). The distribution between DVT and PE was consistent with previous 
studies, 80 % DVT and 20 % PE. 
Villani et al performed a prospective cohort study comparing VTE incidence of 234 women 
who had a clinical pregnancy after ART to a reference cohort of women who gave birth in the 
same region, spontaneously conceived in 2002-2011 84. They found a VTE incidence of 8.5 
per 1,000 compared to 1.8 per 1,000 in controls, (OR 3.9, 95 % CI 0.87-15.3) with this small 
sample thus no significant result. OHSS was found in 4.3 % of the ART population, of which 
none developed a VTE though only 30 % received thromboprophylactic treatment. They 
found thrombophilia in 10.3 % of the women in the ART group and one of those experienced 
a VTE.  
Hansen et al in 2012 found, as mentioned, no association to VTE after unsuccessful ART. In 
a French study by Filipovic-Pierucci et al, they did find such an association studying fertility 
treatments in a nationwide study in France in women undergoing fertility treatments 
including ART with ovarian stimulation 85. They studied 788,007 treatment cycles resulting 
in 82,821 deliveries in 82,174 women during the years 2013-2015 and compared the 
incidence of both venous and arterial thromboembolism in different treatment groups to a 
control group of non-pregnant women and women with a spontaneous pregnancy 
respectively. Interestingly as mentioned, they found an association between ovarian 
stimulation not leading to pregnancy and VTE, with an incidence rate of 3.4 per 10,000 
person-years (95 % CI 1.2.0-5.5) and as compared with a non-pregnant control group an 
incidence rate ratio (IRR) of 1,76 (95 % CI 1.31-2.37). In the group of women who delivered 
after ART with ovarian stimulation they found an incidence of 3.3 per 1,000 compared to 
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spontaneous pregnancies IRR 1.32 (95 % CI 1.08-1.62), adjusted for age and multiple births 
compared to spontaneous pregnancies.  
From the RIETE- registry, an ongoing multi-centre study collecting real world data on VTE 
cases in different centres since 2001, an observational study was conducted on VTE events in 
women of childbearing age during 2001-2016, which revealed 6,718 VTEs of which 41 were 
ART-related VTE. The events of VTE were as many in absolute numbers in ART leading to 
pregnancy (n=20) as in unsuccessful ART (n=21). Most of the VTE occurred in the first 
trimester, 14 out of 20 events (70 %) 86.  
In summary, there is an association between ART and the incidence of VTE in women giving 
birth after ART and a particular risk in OHSS. There is still a need of further development of 
the ART treatment and prophylactic treatment recommendations.  
 
1.10 HAEMOSTASIS  
Haemostasis is the process when the body reacts on a bleeding with a response to minimise 
blood loss. The system is strictly regulated in order to prevent excessive clot formation with a 
close interaction between endothelium and the circulating blood components. When the 
endothelium is injured there is an immediate response of vasoconstriction, which is followed 
by platelet adhesion and aggregation forming the initial platelet plug. When further repair is 
necessary or endothelium activation continues further activation of both the platelets and the 
coagulation cascade occurs to generate thrombin and to form fibrin networks stabilising the 
plug. When the system is in disorder it can cause thromboembolism or bleeding problems.   
As soon as a clot is starting to form to repair the injured vessel there is also a process of 
inhibition of excessive clot formation and dissolution of the clot through fibrinolysis.  
 
1.10.1 Primary haemostasis 
The injured or dysfunctional endothelium exposes adhesion factors such as collagen and von 
Willebrand factor (vWF), which bind to both the subendothelium and to platelets that thus 
adhere to the vessel wall and form the initial platelet plug. The platelets will be activated and 
undergo major shape change, shifting their negatively charged inner membrane of 
phospholipids to the outside and develop long pseudopodia that facilitate further adhesion 
and aggregation.  
The activated platelets secrete a number of prothrombotic proteins, including adhesion 
proteins and coagulation factors, from their granules and expose these proteins on their own 
surface. This further activates and facilitates platelet aggregation and adhesion to endothelial 
cells and leukocytes. The activated platelets also bud off small vesicles termed   
microvesicles (MVs). These platelet-MVs (PMVs) are thus both markers of platelet 
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activation and also act procoagulant since they, like their parent cell, provide a negatively 
charged phospholipid surface for the coagulation factors to assemble on and take part in 
amplification and propagation of coagulation with increased thrombin generation and fibrin 
formation, in the so called cell-based model of haemostasis.  
 
1.10.2 The cell-based model of haemostasis and secondary haemostasis 
The cell-based model of haemostasis describes the coagulation process in three phases, 
initiation, amplification and propagation and in the model the primary and secondary 
haemostasis are intertwined leading to the formation of a clot 87, see figure 6. The process 
includes the activated platelets and MVs that provide a surface for the coagulation factors to 
assemble on and multiply in the cascade of enzymatic reactions leading to thrombin 
generation and fibrin networks that form the clot. 
 
Figure 6. The three phases of coagulation. 
 
 
The main initiator is tissue factor (TF) exposed by the injured endothelium or by other TF-
bearing cells such as monocytes or MVs. TF binds to and activates coagulation factor VII and 
the complex, TF-factor VIIa, activates factor X. Activated factor X (factor Xa) together with 
activated factor V (factor Va) then activate prothrombin (factor II), resulting in a small 
































In the amplification phase the small amount of thrombin generated further activates platelets 
at the site of injury and also activates factor V, factor VIII and factor XI. 
In the propagation phase, TF-VIIa-complex activates factor IX to factor IXa, which together 
with factor VIIIa gather on the phospholipid surface of activated platelets or MVs in the 
presence of calcium and factor X. This complex of factor IXa-VIIIa, the tenase complex, 
rapidly activates factor X that also assembles on the platelet or MVs and forms the 
prothrombinase complex of factor Xa-factor Va in the presence of calcium.  
Large amounts of thrombin are now generated that can cleave fibrinogen to fibrin monomers 
which are cross-linked and stabilised by factor XIII.  
 
1.10.3 Regulatory processes  
There are several regulatory processes involved in haemostasis of which some are mentioned. 
The initiation of coagulation with TF and factor VIIa is inhibited by the tissue factor pathway 
inhibitor (TFPI) by inhibiting activation of factor X. Thrombin as one of the most important 
coagulation factors, that converts fibrinogen to fibrin, activates other coagulation factors and 
platelets directly, needs to be inhibited through several mechanisms. AT is one of these 
important natural inhibitors of thrombin by forming the thrombin-antithrombin           
complex (TAT) and AT also inhibits factor IXa, factor Xa and factor XIa. AT is the target of 
anticoagulant treatment with low molecular weight heparins (LMWH). The third important 
inhibitor is APC which inactivates factor Va and factor VIIIa with protein S as a co-factor. 
This step is activated by thrombin binding to thrombomodulin on endothelial cells activating 
protein C. A deficiency of any of these three proteins AT, protein C or S entails an increased 
risk of developing VTE 88.  
 
1.10.4 Fibrinolysis  
As soon as a blood clot is formed fibrinolysis starts and degradation products, such as D-
dimers are formed, that can be measured in plasma. Plasminogen is a protein bound to fibrin 
surfaces and it is activated by tissue plasminogen activator (tPA) to plasmin. The activated 
plasmin starts the dissolution of the clot and degradation products will be formed. The 
fibrinolytic process is regulated by plasminogen activator inhibitor-1 (PAI-1) and during 
pregnancy the placental plasminogen activator inhibitor-2 (PAI-2) and thrombin activatable 
fibrinolysis inhibitor (TAFI) in order to slow down fibrinolysis and prevent bleeding.  
Thrombin is thus both a major activator of platelets and coagulation, converting fibrinogen to 
form fibrin, but also a regulator of anticoagulant and fibrinolysis-inhibiting pathways. 
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1.10.5 Microvesicles  
One way of studying cell-based haemostasis and platelet function is to study changes of the 
procoagulant MVs. The most abundant plasma circulating MVs are the above mentioned 
platelet-MVs (PMVs) released from activated platelets. MVs can also derive from a variety 
of other cells, such as endothelial cells, leukocytes and erythrocytes following activation or 
apoptosis. MVs are small, membrane-coated, sized 0.1-1 µm in diameter and as mentioned 
they share the protein composition of their parental cell and carry surface proteins with 
various biological effects that can be transferred to other cells. MVs are thus important in 
transcellular signalling and communication and have been associated with both inflammatory 
and prothrombotic processes 89.  
Studies of changes in MVs and their protein composition over time in disease or compared to 
healthy controls can reveal pathophysiological mechanisms in various diseases and MVs 
have been found elevated in both cardiovascular disease such as acute coronary syndrome 90, 
peripheral arterial disorder 91 and in diabetes 92. The MVs procoagulant properties can be 
attributed to the surface layer of phospholipids with the phophatidylserine (PS) that provides 
the surface for the assembly of coagulation factors, but also through the exposure of TF and 
other procoagulant proteins 93 94 95.  
Regarding VTE, many studies on MV levels in VTE-patients have been performed on 
cancer-patients, but there are also studies to be found on VTE in general. In a case-control 
study of 186 patients with a first VTE, they found increased levels of all PS-positive MVs, 
MVs of platelet-origin and MVs bearing TF analysed by flow cytometry compared to in 418 
controls, adjusted for age, body mass index (BMI), sex and thrombophilia 96. Another study 
compared MV levels as measured by flow cytometry in 25 VTE patients to 25 controls and 
found increased levels of endothelial-MVs (EMVs) 97. In hereditary thrombophilia increased 
levels of PS-positive MVs, PMVs, EMVs and TF-bearing MVs have been found in carriers 
of factor V Leiden gene mutation 98, prothrombin gene mutation 99 as well as in AT-, protein 
C- and protein S-deficiencies compared to healthy controls 100. In all thrombophilia studies 
they also found an association between carriers of the deficiencies of the natural coagulation 
inhibitors who had experienced a previous VTE and higher levels of MVs 100.  
Platelet activation as measured by P-selectin and CD40 ligand (CD40L), both released from 
platelets upon activation, have been examined in thrombotic disease such as VTE and also in 
complicated pregnancies or spontaneous abortion. P-selectin has been associated with VTE in 
mouse models with decreased venous thrombosis when treated with P-selectin inhibitor 101. 
In a study of 28 patients with a previous idiopathic DVT an association was found between 
soluble P-selectin and the VTE-patients compared to age-and sex-matched controls 102. In the 
same study they found no elevation of CD40L. In another study of 304 women with a 
previous VTE who had experienced at least one spontaneous abortion, they found that 
stillbirth after pregnancy week 24 was associated P-selectin level, but not with miscarriages 
before that week in women who had a history of a VTE 103. The receptor for P-selectin, P-
selectin glycoprotein ligand-1 (PSGL-1) has also been found increased as carried by 
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monocyte-MVs (MMVs) and EMVs in patients with a previous idiopathic VTE compared to 
in age-matched healthy controls 104. P-selectin released soluble to the circulation or 
membrane-bound exposed on PMVs could both interact with leukocytes by binding to the 
PSGL-1 mostly expressed on leukocytes. 
 
1.11 HAEMOSTATIC CHANGES IN PREGNANCY  
The haemostasis changes during pregnancy towards a hypercoagulative state which 
contributes to the regulation of blood loss during delivery, though the uterine contraction at 
delivery is the most important factor to stop postpartum-bleeding. Uterine atony is one of the 
leading causes of maternal death in developing countries.  
During pregnancy there is an increase of coagulation factors, especially factor VIII 105 106, 
factor X 105, factor XII 105, vWF and fibrinogen 107 106. With a progressing pregnancy the 
coagulation inhibitors decrease. Antithrombin decreases in most studies, at least towards the 
end of pregnancy and still postpartum 108, but remains unchanged in some studies 109. Protein 
S decreases 107 110 and APC-resistance increases 111 during the progress of pregnancy, while 
various studies have described protein C levels to both increase 112 and decrease or to remain 
unchanged 107 113. 
All this together with an impaired fibrinolysis contributes to the hypercoagulative state that 
progresses during pregnancy along with the great increase in oestrogen level as indicated 
previously 114-116. The levels of PAI-1 and naturally the placenta-produced PAI-2 increase 
later in the pregnancy 110 112. Regarding tPA various data exist with some studies finding 
increased levels 107 and some decreased 117. In one study of 48 uncomplicated pregnancies 
they found besides an increased PAI-1 and PAI-2 levels a decreased level of tPA throughout 
pregnancy 112, while another study of 41 women with uncomplicated pregnancies indicated a 
decrease of tPA during the first trimester followed by an increase in late pregnancy 118. This 
was speculated to be due to an increased fibrinolysis during late pregnancy as a natural 
protection, a way to counteract the hypercoagulability. They found the same increase of PAI-
1 and PAI-2 and all levels returned to pre-pregnancy values six weeks postpartum. Increased 
D-dimer through pregnancy suggests increased fibrinolysis as well as a hypercoagulative 
state. Other possible counteractors are the increased levels of the coagulation inhibitor TFPI 
that has been found to be increasing during pregnancy 119.  
Other studies using global haemostasis assays have found increased coagulation parameters 
in TEG 120 and in ETP and peak thrombin as measured by the calibrated automated 
thrombogram (CAT) 109.  
The most common findings in haemostatic parameters are presented in table 2. Regarding 
some of the factors, studies have shown varying results and some factors vary by trimester. 
Factor II and factor V have been found to be elevated during early pregnancy and to decrease 
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to normal levels by the third trimester 106. Factor IX and XI have also been shown to both 
increase and decrease in the different trimesters and postpartum.  
Factor XIII that stabilises the clot has mostly been found to be decreased in pregnancy but 
there are conflicting data. In one study they thus assessed more parameters simultaneously, 
such as clot strength as measured by thromboelastography (TEG), fibrinogen and platelet 
counts simultaneously and repeatedly during pregnancy and compared these values at 8 
weeks postpartum as a reference, with different time points during pregnancy to assess 
possible relations 121. They found that factor XIII activity decreased during pregnancy, while 
platelet counts decreased and fibrinogen increased and both were positively correlated to clot 
strength, while factor XIII activity was not.  
Platelet aggregation has recently been assessed in women giving birth with repeated blood 
sampling during pregnancy and postpartum and compared to the postpartum samples and to a 
control group of fertile women, they found a minor decrease in platelet aggregation during 
pregnancy compared to postpartum and to healthy, non-pregnant controls 122. Platelet 
activation and aggregation was induced by arachidonic acid, adenosine diphosphate (ADP), 
collagen and thrombin receptor activating peptide-6 (TRAP-6).  
In pregnancy PMVs and EMVs have been found elevated compared to in non-pregnant 
women 123. MVs in uncomplicated pregnancies have been found elevated in the first trimester 
compared to healthy, non-pregnant controls and the MV levels increased with gestational   
age 124. 
Sex differences in MV levels have been investigated and in a study of premenopausal women 
compared to age-matched men 125. The women were found to have elevated PS-positive MVs 
with PMVs expressing P-selectin, detected by flow cytometry. The difference was largest 
during the women’s luteal phase. 
In recently menopausal women MVs were assessed by flow cytometry in two groups as 
divided by E2-level 126. Twenty-one of the women had low oestradiol levels (E2 ≤20 pg/ml 
corresponding to around ≤70 pmol/L) and 11 of the women had higher levels (E2>40 pg/ml 
corresponding to around >150 pmol/L). PS-positive MVs and MVs exposing TF as well as 
all other MVs measured, derived from endothelial cells, monocytes, and granulocytes and 
were significantly increased in the group of women with low endogenous oestrogen.   
 
1.12 HAEMOSTATIC CHANGES IN ASSISTED REPRODUCTIVE TECHNOLOGY 
Most studies on haemostasis during ovarian stimulation have found that the procoagulative 
parameters increase concomitant with a decrease in natural anticoagulants and an impaired 
fibrinolysis with a close similarity to what is found during pregnancy.  
In table 2 the changes are presented during pregnancy respectively during ART. 
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Increased levels have been found of coagulation factors II, VIII, IX 127 128, von Willebrand 
factor 127 and increased fibrinogen 127 129. Factor VII has remained unchanged 129 or with 
decreased levels 127. Factor V have been found decreased 130.  
Westerlund et al performed studies on global haemostasis in women undergoing ovarian 
stimulation, which is also the study population of study I and II in this thesis. They assessed 
with the CAT assay the endogenous thrombin potential (ETP) and analysed also overall 
haemostasis potential (OHP) and found an increased thrombin generation as exemplified by 
ETP and an increased fibrin formation by the OHP method 42.  
Regarding coagulation inhibition TFPI has been found to decrease 130 131. APC-resistance 
increased towards late pregnancy 132. Decreased levels have been found of AT 127 129 130 133, 
protein C 127 as well as protein S in one study 132, while the latter had a tendency to increase 
in another 127. 
Furthermore, as in other pregnancies an impaired fibrinolysis has been found during 
pregnancy with decreased levels of tPA 134, but PAI-1 also decreased in this study while  
PAI-2 increased. 
MV studies during ART are scarce. In a study of recurrent implantation failure in women 
conceived by ART by a Spanish research group, it was noted increased MV levels following 
recurrent implantation failure after ART as compared to in those with successful ART 












Coagulation factors   
Fibrinogen   
Factor II  various  
Factor V  various  
Factor VII various various 
Factor VIII   
Factor IX   
Factor X -    
Factor XI       - various 
Factor XII       -  
Factor XIII various          
von Willebrand factor   
Coagulation inhibitors   
Antithrombin           
Protein C  various 
Protein S various         
APC-resistance   
Fibrinolytic factors   
tPA  various  
PAI-1 various  
PAI-2   
Cell-derived microvesicles   
Microvesicles (MV) -  
Platelet-derived MV (PMV) -  
MV exposing P-selectin -  
MV exposing tissue factor -  
Leukocyte-derived MV -  
Endothelial-derived MV -  
Global haemostatic assays   
Thromboelastography   
Overall haemostasis potential   










The overall aim of this thesis was to gain increased knowledge of the association between 
assisted reproductive technology (ART) and venous thromboembolism (VTE) with focus on 
the effects of ovarian stimulation and its hyperoestrogenism as a potential cause of the 
procoagulative state and increased VTE-risk found in ART after ovarian stimulation.  
The specific aims of the three studies were:  
• Study I: To study the effects of ART with ovarian stimulation on circulating plasma 
microvesicles exposing procoagulative and inflammatory markers. 
 
• Study II: To explore the changes of the protein composition (proteome) of the plasma 
microvesicles during ovarian stimulation in ART to identify physiological and 
potential patophysiological mechanisms that could potentially contribute to a 
prothrombotic state.  
 
• Study III: To assess the incidence of VTE and PE in women giving birth after ART 
using fresh embryo transfer, when the transfer was performed directly after the 
ovarian stimulation cycle, or when a frozen-thawed embryo transfer was performed in 
a later cycle, and compare to the incidence of VTE and PE after ET to that in women 





3 MATERIALS AND METHODS 
 
3.1 STUDY POPULATION AND STUDY DESIGN 
3.1.1 Study I and II – The microvesicle studies 
3.1.1.1 Study population 
The study population of study I and II consisted of 31 women undergoing ART treatment 
with ovarian stimulation at Huddinge Hospital in Stockholm, Sweden in 2008-2009, see 
figure 7. The women were consecutively included by Westerlund et al as previously 
described, unless they met the exclusion criteria: previous arterial or venous 
thromboembolism, family history of VTE, coagulation disorder, cardiovascular disease, 
hypertension, hyperlipidemia, diabetes mellitus, active or previous history of a malignant or 
systemic inflammatory disease 42.  
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Some of the patient characteristics are presented in table 3. 
 
Table 3. Characteristics of  the 31 patients in study I and II. 
 
 
All women received the long hormone protocol using a GnRH-agonist, which was started on 
day 21 of the menstrual cycle with a nasally administered spray (Buserelin). Approximately 
two to two and a half weeks later a down regulation (DR) of the ovaries was achieved with 
oestradiol levels below 150 pmol/L, and thereafter the ovarian stimulation was started with 
subcutaneous injections of FSH (Gonal-F) administered for 10-14 days. Repeated ultrasound 
images of the ovaries were performed during the ovarian stimulation to regulate follicular 
development by dose adjustments and finally hCG was administered subcutaneously 36 hours 
before planned oocyte retrieval.  
3.1.1.2 Blood sampling 
Blood samples were collected at two occasions as shown in figure 8, through direct 
venepuncture under overnight fasting conditions and after 20 minutes of rest, sitting down. 
The first sample was taken two to two and a half weeks after treatment start, at maximum DR 
when oestradiol levels were <150 pmol/L and a menstrual bleed had occurred. The second 
sample was taken at high level stimulation (HLS) before hCG was administered.  
The blood was collected in citrated tubes (containing nine parts of blood and one part of 
sodium citrate) and in EDTA-tubes. The samples were immediately centrifuged at 2000 g for 
20 minutes at room temperature to obtain platelet poor plasma (PPP) and aliquots of 500 µL 





Age, years 33.0 ± 3.3 
BMI, kg/ m2 24.1 ± 3.6 
Smoking, n (%) 2 (11) 
Female cause of infertility, n (%) 7 (22) 
Male cause of infertility, n (%) 12 (39) 
Unknown, n (%) 12 (39) 
Standard IVF/ICSI/discontinued, n 21/9/1 
Clinical pregnancy, n (%) 12 (39) 
Ovarian hyperstimulation syndrome, n (%) 3 (9.7) 
Age and BMI=body mass index presented as means and 
standard deviation. Other data in numbers and proportion 
of patients. n=number. 
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Figure 8. Treatment protocol in study I-II. 
 
 
3.1.1.3 Study design  
The studies were performed by analysis of blood samples before and during ovarian 
stimulation. Each patient served as their own control with comparisons of samples before and 
during ovarian stimulation. 
3.1.1.4 Ethical approval and considerations 
The studies were performed in accordance with the ethical principles of the Declaration of 
Helsinki for medical research. The studies were approved in 2006 by the Regional Ethical 
Review Board in Stockholm, Sweden, reference number 2006/1222-31/1. All patients gave 
their informed consent to participate in the study with a consent to store blood samples in the 
research biobank. They were all informed that they could demand to be excluded from the 
study at any time and of their right to ask for their individual data results and for their 
samples to be destroyed or unidentifiable.  
 
3.1.2 Study III – The observational study 
3.1.2.1 Study population and study design 
The study population in study III consisted of all deliveries from the Swedish Medical Birth 
Register (MBR) 136 in Sweden registered in 1992-2012, see figure 9. Up until 2006 
information on ART was collected and presented as the IVF part of the registry and since 
2007 collected by the National Quality Registry of Assisted Reproductive Technology (Q-
IVF) 36. Out of the women with child births during this period as identified in the MBR we 
sorted out the women that were found in the IVF-part of the MBR and in the Q-IVF which 
constituted a cohort of all ART pregnancies. In our study design we wanted to study women 
with first child births in all groups and the first incident outcome VTE or PE. Thus we 
excluded all women with a previous child birth and all women with a previous VTE. We also 
chose to include women who were 15-50 years old. A total of 30,328 women with a first 
delivery constituted all women after ART and they were further divided into the groups of 
25,382 women who were conceived after fresh ET and the 4,946 women who had a frozen 
Down Regulation (GnRH-agonist)
Ovarian stimulation (FSH)
Day 21 of menstrual cycle 1st blood sample 2nd blood sample
hCG
Oocyte retrieval






ET. The rest of the pregnancies were considered as spontaneous pregnancies and numbered 
872,563 women with a first delivery. 
 
Figure 9. Study population in study III. 
 
 
3.1.2.2 The registries 
The registries used in this study were thus the MBR and the Q-IVF registry 36 for study 
population and further the National Patient Register (NPR) in Sweden for all diagnoses of 
VTE, the Swedish Register of Education 137 for information on completed years of education 
and the Swedish Cause of Death Register 138 for death in the postpartum period. All 
information in the registries mentioned are based on the unique Swedish identity number.  
The MBR held at the National Board of Health and Welfare contains detailed information on 
97-99.5 % of all child births in Sweden since 1973 with information obtained from prenatal, 
delivery and neonatal care and up until 2005 births from pregnancy week 28 were included 
and from 2005 and on from pregnancy week 22 136. As mentioned, information on all ART 
was included in the MBR from 1982 until 2006 with information concerning for example 
ART method and date of ET.   
Since 2007 the Q-IVF collects information on all ART treatments in Sweden and not only 
deliveries. It contains detailed information, such as on treatment protocols used, dates of 
treatment start and of all other registered events, whether own or donated oocytes and sperm 
were used, fertilisation method (IVF or ICSI), number of embryos transferred and whether a 
clinical pregnancy was achieved or not 3.  
The NPR started registering inpatient diagnoses in the 1960s, but it was not until 1987 that 
the reporting was made mandatory in Sweden on all in-patient care in the register that is held 
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by the National Board of Health and Welfare. In 1997 also outpatient diagnoses were 
introduced and in 2001 all specialist outpatient care are included. The coverage is considered 
high concerning the inpatient part of the registry and the validity is high for most      
diagnoses 139. Regarding the outpatient diagnoses the first year is considered to be potentially 
underreported for many diagnoses. The diagnoses are coded according to the International 
Classification of Disease (ICD), which has been released in different versions and today since 
1997-98 the ICD-10 is used in Sweden.  
Statistics Sweden are responsible for the Education Register, which contains information 
such as the highest educational level completed.  
3.1.2.3 Ethical approval and considerations 
The study was performed in accordance with the ethical principles of the Declaration of 
Helsinki for Medical Research. Ethical approval was granted in 2009 by the Regional Ethical 
Review Board in Stockholm, Sweden, reference number 2010/267-31/4, and in 2013, 
reference number 2013/1849-31/2. All registry-data are as mentioned decoded on beforehand 
at the National Board of Health and Welfare and since the personal identity number is 
replaced with a serial number no individuals can be identified by the researchers or in the 
event of data intrusion, which is important since registry data does not require personal 
consent to be used in research.  
 
3.2 METHODS AND STATISTICAL ANALYSIS 
3.2.1 Study I – The microvesicle study 
3.2.1.1 Microvesicle analysis 
The frozen samples of PPP were thawed and centrifuged a second time during 20 minutes at 
2,000 g in room temperature (RT). The supernatant was then re-centrifuged at 13,000 g for 2 
minutes at RT and 20 µL of the supernatant was incubated during 20 minutes in the dark with 
phalloidin to exclude cell fragments as previously performed in our research group 140. 
A flow cytometer (Beckman Coulter Gallios) was used to detect and quantify the MVs. The 
flow cytometry sorts the cells based on size, shape and fluorescence 141. In the analysis cells 
pass through a laser beam in a solution and when the light falls on each cell it is spread or 
scattered in a certain manner depending on size and granularity, which allows for each cell to 
be determined. The side scatter of the light determines complexity or granularity, while size is 
determined by the forward light scatter and calibration beads of known sizes are used as a 
reference to compare size. In this study a mix of beads of the sizes 0.5, 0.9 and 3.0 µm was 
used.  
Annexin V or lactadherin are proteins used to detect the negatively charged phospholipid 
surface exposure. Lactadherin binds to PS without requiring calcium and in this study 
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fluorescence-labelled lactadherin was used to identify the total MV counts as PS-positive 
MVs. Further, specific fluorescence-labelled monoclonal antibodies were used to detect cell 
origin and activation markers.  
MVs were defined as vesicles smaller than 1.0 µm, negative to phalloidin and positive to 
lactadherin, PS-positive, and further phenotyped by the chosen monoclonal antibodies in our 
study protocol. They were calculated as absolute numbers given in MVs/L by a formula of 
(MV count x standard beads/L)/standard beads counted.  
Our MV protocol, seen in figure 10, aimed to determine all MVs as PS-positive MVs and 
further phenotype them into platelet-MVs (PMVs) as MVs positive for CD42a and PMVs 
with platelet activation markers CD62P for P-selectin, CD154 for CD40 ligand or CD40L, 
endothelial MVs (EMVs) as positive for CD62E for E-selectin or CD144 for VE-cadherin 
and monocyte-MVs (MMVs) as MVs positive for CD14 and for neutrophile-MVs (NMVs) 
as MVs positive for CD15. 
 




3.2.1.2 Statistical analysis of the microvesicles 
The MV distribution showed a skewness to the right even after log transformation, which was 
both visually seen in the histogram and confirmed by Shapiro-Wilks test for normality. Thus, 
the statistical analysis was performed by non-parametrical tests.  
Data is presented as medians and interquartile ranges (IQR) for the continuous variables such 
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were performed by Wilcoxon signed-rank-test for dependent data or matched pairs. The two-
tailed significance level was set to 0.05. Sample size of at least 31 patients had been 
calculated in advance to achieve a desired power of at least 80 % power to detect a difference 
of 20 % between the samples at a 5 % significance level. Simple linear regression analysis 
was performed to test the relationship between variables. The flow cytometric analysis had 
previously been performed on MVs in healthy controls by repeated measurements on two 
different flow cytometers in different laboratories with intra- and interassay coefficient of 
variation below 10 %. 
 
3.2.2 Study II – The microvesicle proteome study 
3.2.2.1 Proteomic analysis of the microvesicles 
Several proteomic techniques are available to detect and measure the abundance of proteins. 
In this study liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) was 
used to determine the protein composition of MVs. The analysis was performed on the MV-
enriched samples prepared, to identify and quantify changes of the proteins carried by the 
MVs during ovarian stimulation. 
The proteomic analysis is complex with many steps, both in the laboratory setting and in the 
data processing with the use of several software programs that handle large scale 
bioinformatics and determine the protein by matching the unique peptide sequences of the 
analysed material with previously known data. In this study liquid chromatography combined 
with tandem mass spectrometry (LC-MS/MS) was used according to the detailed, previous 
description in the published article 142. 
The proteins or peptides of a sample need to be prepared before analysis, which was achieved 
by liquid chromatography (LC) after incubation with trypsin which digested the proteins into 
peptides. The peptides were then separated by LC analysis that was coupled to the tandem-
MS analysis in order to identify and quantify the proteins through the unique peptides by the 
mass-to-charge ratio giving the abundance. Data was further analysed by software analysis 
for peptide identification of the raw data with a predetermined requirement of at least two 
unique peptides consisting of minimum length of 6 amino acids identified per protein and 
with a false discovery rate (FDR) of 1 %.  
3.2.2.2 Statistical analysis of the proteomic analysis 
The data was log-transformed due to skewness in the distribution and was confirmed to be 
normally distributed after log2-transformation. Comparisons of protein abundance before and 
during ovarian stimulation were assessed by moderated paired t-test using the limma  
package 102. Proteomics and other studies on large scale data entail a risk of achieving a large 
number of significant results by chance due to the multiple comparisons that can lead to false 
positive and inaccurate interpretations. Thus, adjustment for multiple comparisons should be 
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performed. We used correction for the multiple comparisons using Benjamini-Hochberg 
adjustment of the false discovery rate (FDR) and set the significance level to 1 %, the 
adjusted P-value, often referred to as q-value less than 0.01.  
 
3.2.3 Study III – The observational study 
3.2.3.1 Registry data 
Data was collected from the registries with the study population from the MBR as described 
above where all women were aged 15-50 years old with their first child born during the study 
period from the 1st of January 1992 until the 31st of December 2012. 
The exposures were either pregnancies achieved by ART by a fresh ET or by a frozen ET and 
those were compared respectively to the reference group of spontaneous pregnancies. The 
reference group comprised the women found in the MBR that were not included in the IVF-
registry part or Q-IVF and were thus considered to be spontaneous pregnancies.  
The outcome VTE was defined as the first incident diagnose of VTE and secondary outcome 
was first incident PE during the time period. All women with a previous VTE were excluded.  
For the outcomes the ICD-codes included were for PE (ICD-8: 450.01-03, 450.09, 673.98-
99; ICD-9: 415B, 673C; ICD-10: I26.0, I26.9, O882), for DVT (ICD-8: 451.00, 451.98-99, 
671.01-02, 671.08-09; ICD-9: 451B; ICD-10: I80.1-3, I80.8-9, O22.3, O87.1), portal vein 
thrombosis (ICD-8 453.09; ICD-9: 452; ICD-10: I81.9), vena cava thrombosis (ICD-8; ICD-
9: 453C; ICD-10: I82.2), renal thrombosis (ICD-8; ICD-9: 453D; ICD-10: I82.3), cerebral 
vein thrombosis (ICD-8: 321.00, 321.09; ICD-9: 325; ICD-10: O22.5, O87.3) and diagnoses 
codes for other localizations of DVT or emboli (ICD-8: 453.09; ICD-9: 453W, 453X, 671F; 
ICD-10: I82.8-9, O87.9). 
The follow-up period included time from the start of the pregnancy until an event occurred or 
until 42 days postpartum. Trimesters were determined as day 0-90 for first trimester, day 91-
181 for second trimester and day 182 until three days before delivery date for third trimester, 
and two days before delivery date and 42 days after delivery for postpartum.  
3.2.3.2 Statistical analysis  
Incidences of the outcomes VTE and PE were calculated as events per 1,000 pregnancies 
with all antepartum and postpartum periods included.  
Hazard ratios (HR) with 95 % confidence intervals (CI) were estimated by Cox regression 
models for the two different exposures, fresh and frozen ET and compared to spontaneous 
pregnancies, which was defined as the non-exposed or reference group. HRs were estimated 
for the entire period including all trimesters and the postpartum period.  
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We performed two models, where the first model calculated crude hazard ratios and the 
second model had adjustments made for the potential confounding factors: age at        
delivery (<25, 25-29, 30-34 or ≥35 years), pre-pregnancy BMI (<25, 25-29 or ≥30 kg/m2), 
single or multiple birth, pre-pregnancy cigarette smoking, calendar period of diagnosis split 
into 5-year intervals (1992-1996, 1997-2002, 2003-2007, 2008-2012), educational level (≤9, 





4 RESULTS AND DISCUSSION 
 
4.1 STUDY I – THE MICROVESICLE STUDY 
4.1.1 Results 
In table 4 the previously analysed haemostatic parameters in the study population performed 
by Westerlund et al are presented 42. As previously mentioned the oestradiol levels increased 
10-100-fold from the down-regulated level at DR compared to during the final phase of the 
ovarian stimulation just before hCG-administration, HLS, as denoted above in the description 
of study population and design. Their findings showed increased fibrinogen, factor VIII and 
thrombin generation as assessed by ETP by the CAT assay 42 143. 
 
Table 4. Baseline values and change in oestradiol and some haemostatic parameters.   
Reprinted with permission from publisher 144.  
 
The medians of MV counts were calculated and presented with interquartile ranges (IQRs) 
and values at DR and HLS were compared.  
MVs included in the analysis are shown in the protocol in figure 10. MVs were defined as 
those positive to lactadherin and further as PMVs when positive to CD42a, EMVs exposing 
E-selectin as positive to CD62E, EMVs exposing VE-cadherin as positive to CD144, MMVs 
as positive to CD14 and NMVs to CD15. Further, PMVs exposing activation markers P-





Mean ± SD 
HLS 
Mean ± SD 
Reference   
interval P-value 
Age, years 33.0 ± 3.3        
BMI, kg/m2 24.1 ± 3.6     < 25  
Haemoglobin, g/L 129.0 ± 8.6    117 - 153  
Leukocyte particle conc x109/L 5.1 ± 1.2    3.5 - 8.8  
Platelet particle conc x109/L 251.2 ± 47.6    165 - 387  
Creatinine, μmol/L 68.9 ± 7.3     < 90  
LDL-cholesterol, mmol/L 2.9 ± 0.7    1.4 - 4.7  
Plasma glucose, mmol/L 4.7 ± 0.5    4.0 - 6.0  
Oestradiol, pmol/L 106 ± 31 5,889 ± 4,723    <0.001 
Fibrinogen, g/L 2.8 ± 0.7 3.3 ± 0.7 2.0 - 4.0 <0.001 
FVIII, kIU/L 0.96 ± 0.34 1.26 ± 0.41 0.5 - 1.8 <0.001 
Peak, nM IIa 290 ± 42 343 ± 38    <0.001 
ETP, nM IIa*min (AUC) 1,542 ± 287 1,739 ± 288       <0.001 
DR=down regulation, HLS=high level stimulation, SD=standard deviation, BMI=body mass 
index, LDL=low density lipoprotein, ETP=endogenous thrombin potential, AUC=area under 




As seen in figure 11, we found a significant increase in most of the MVs analysed by the 
specific monoclonal antibodies according to our protocol.  
The most abundant MVs were PMVs, which is a common finding in MV analyses and makes 
MV analysis a way of studying changes of platelet function and platelet activation. PMVs 
exposing P-selectin (CD62P+) and CD40 ligand (CD154+) were both significantly increased 
as seen in figure 12.  
Further, we analysed EMVs as MVs exposing the adhesion molecules E-selectin and VE-
cadherin, both adhesion molecules and indicators of endothelial activation. EMVs exposing 
E-selectin (CD62E+) were significantly increased, while EMVs exposing VE-cadherin 
(CD144+) remained unchanged. The only group of MVs that were slightly decreased where 
NMVs (CD15+).  
In the study population three out of 31 (9.7 %) women were diagnosed to have developed 
OHSS and comparison of overall PS-positive MV levels in these three women to the rest of 
the women showed that overall MVs were four-fold increased as compared to the other 28 
women, with a tendency towards significance (p=0.072).  
To assess correlations between the variables we performed simple linear regression analysis. 
No associations were found between oestradiol levels and MV levels. The material was then 
divided using oestradiol levels by a median split, to those with values above and below the 
median. We then performed a regression analysis of the previously analysed haemostatic 
parameters and found a correlation between oestradiol levels above the median at HLS and 
peak thrombin at HLS. 
 
4.1.2 Discussion 
We found that the levels of circulating PS-positive MVs increased during ovarian stimulation 
indicating a procoagulant state with an increased amount of phospholipid surfaces available 
for coagulation.  
PMVs were the most abundant and increased significantly and PMVs exposing P-selectin and 
CD40L doubled during ovarian stimulation indicating platelet activation and an increased 
possibility of cross-talk between inflammation and haemostasis since they are both released 
from the platelet granules upon activation and can bind to receptors on other cells such as 







Figure 11. Microvesicles before (DR) and at (HLS) ovarian stimulation. Reprinted with 






DR=down regulation, HLS=high level stimulation, IQR=interquartile range, MVs=microvesicles, 
PMVs=platelet microvesicles, MMVs=monocyte microvesicles, NMVs=neutrophile 
microvesicles, EMVs=endothelial microvesicles 
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Figure 12. Platelet-microvesicles exposing activation markers P-selectin and CD40 ligand 




Of the leukocyte-derived analysed MVs, the MMVs increased, while NMVs decreased 
slightly. EMVs exposing E-selectin increased, while EMVs exposing VE-cadherin remained 
unchanged 104. There are studies that have found a stronger association to apoptosis in VE-
cadherin 145, which could suggest that ovarian stimulation causes endothelial activation but 
not apoptosis in endothelial cells. 
Platelet activation, as indicated by increased amount of both soluble P-selectin and MV-
bound P-selectin, has been investigated in pregnancies complicated by preeclampsia and in 
pregnancies with spontaneous recurrent abortion compared to uncomplicated pregnancy and 
non-pregnant controls. In one study of PMVs exposing P-selectin in preeclampsia they found 
that the levels were significantly increased in preeclampsia compared to the non-pregnant 
controls, while there was no significant change as compared to normotensive pregnant 
controls 146. All staining for P-selectin also stained for the platelet-specific monoclonal 
antibody (CD61) suggesting that most P-selectin reflect platelet activation. In preeclampsia 
the platelet numbers decreased, which in turn decreased overall PMVs, yet the fraction 
exposing P-selectin was as mentioned increased. In two studies on of P-selectin during 
pregnancy the women who developed preeclampsia had significantly elevated levels at the 
end of the first trimester, suggesting that P-selectin could be a marker of complicated 
pregnancy with preeclampsia 147 148. 
CD40L can be measured both as soluble CD40L and MV-exposed CD40L. Soluble CD40L 
levels have been associated with inflammatory and thrombotic diseases with worse outcome 
in acute coronary syndrome 149. In contrast to our findings, CD40L measured in soluble form 








hCG-administration, followed by increased levels at the day of oocyte retrieval 150. The 
oestradiol mean levels in that study were very similar to those in our study population (5,572 
± SE 3,296 pmol/L) and CD40L seemed to decrease by increasing oestradiol level, but with 
no significant correlation to the also found wide range of oestradiol.  
MVs exposing CD40L have been suggested to be a better marker of inflammation than 
soluble CD40L. This was found in a study of 15 healthy patients with in vitro-induced 
inflammation and flow cytometric MV analysis of MV-exposed CD40L compared to soluble 
CD40L 151. Soluble CD40L was found at significantly higher levels in preeclampsia 
compared to uncomplicated pregnancies, but interestingly with the same levels as the non-
pregnant controls 152. 
An interesting finding was that, though non-significant, the small number of women in our 
study who developed mild OHSS had a four-fold increased MV count as compared to the 
other 28 women. Whether MVs could be biomarkers of OHSS, which in turn could 
contribute to an increase of VTEs in ART pregnancies, needs to be further studied.  
4.1.2.1 Limitations and methodological considerations 
One limitation of our study is the small sample size, but the study design with each patient 
being her own control in the pre-during ovarian stimulation design reduced the risk of 
confounding that could otherwise exist between patients. The design requires fewer patients 
to detect changes with statistical significance, though a statistically significant result might 
not always be of clinical relevance.  
Another limitation of the method is that the detection limit is 0.2-0.3 µm and small MVs 
could be missed. Also we could interpret other particles such as lipoproteins or other small 
vesicles as MVs.  
In this study we did not perform any functional assay of procoagulant properties of the MVs, 
but it has previously been shown that MVs are procoagulant by the expression of PS and  that 
the thrombin generating capacity of PS-positive MVs was high and decreased with blocking 
of PS by lactadherin 91 153. 
 
4.2 STUDY II – THE MICROVESICLE PROTEOME STUDY 
4.2.1 Results 
In total 1,199 proteins were initially identified by LC-MS/MS and further analysis was 
performed on all proteins that were quantified in more than 50 % of the samples as the lower 
limit of detection. Thus, 306 proteins were included in the analysis with comparison of 
protein abundance before and during ovarian stimulation, that is at DR and at HLS and they 
are plotted out in the Volcano plot, see figure 13.  
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Figure 13. Volcano plot of all analysed proteins (n=306) and their change during ovarian 
stimulation. The x-axis represents the logarithm to the base 2 of the fold change (FC) and the 
y-axis the negative logarithm of the adjusted P-value. Dotted line demarks the significance 




In the Volcano plot in figure 13 the changes of proteins are shown with the log 2 of the fold 
change. As previously described, P-values were corrected using Benjamini Hochberg method 
for multiple comparisons. We identified 72 proteins that were significantly changed in 
abundance at HLS as compared to DR, with a significance level <0.01. Out of the 72 
proteins, 28 were up-regulated and 44 down-regulated during ovarian stimulation. In table 5 
all the identified, known proteins are categorised, but since many proteins have several 
biological functions and because those are intertwined the proteins often belong to more than 

















Fibrinogen alpha chain Coagulation factor V 
Fibrinogen beta chain  
Fibrinogen gamma chain  
von Willebrand factor  
Other proteins involved in coagulation 










 Complement C1q subunit A 
 Complement C1q subunit B 
 C4-binding protein alpha chain 
 C4-binding protein beta chain 
 Complement factor B 
 Complement factor I 
 Complement factor C4B 
 Complement component C6 
 Complement component C7 
 Complement component C8 gamma chain 
 Plasma protease C1 inhibitor 
Acute phase proteins and proteins involved in inflammation 
Alpha-1-antitrypsin Alpha-1-antichymotrypsin 
Angiotensinogen Alpha-1-acid glycoprotein 1 
Alpha-2-HS-glycoprotein Alpha-1-acid glycoprotein 2 
Ceruloplasmin Haptoglobin 
 Ig gamma-1 chain C region 
 Ig lambda chain V 
 Ig lambda-2 chain/Ig lambda 3-chain 
 Immunoglobulin J chain 
 Monocyte differentiation antigen CD14 
 N-acetylmuramoyl-L-alanine amidase 
Proteins involved in reproduction 
Fetuin-B  
Pregnancy zone protein  
Sex hormone-binding globulin  
Lipoproteins 
Apolipoprotein A-I Apolipoprotein A-II 
 Apolipoprotein B 
 Apolipoprotein C 
 Apolipoprotein D 
 Apolipoprotein E 
 Serum-Amyloid A-4 protein 
Cytoskeletal proteins 
Actin Gelsolin 
Heat shock cognate 71 kDa protein Proteoglycan 4 
78 kDa glucose-regulated protein  
Miscellaneous 
Carbamoyl-phosphate synthase Cholinesterase 
Corticosteroid-binding globulin Extraceullar matrix protein 1 
Hyaluronan-binding protein Glutathione peroxidase 
Hemoglobin subunit alpha Transthyretin 
Hemoglobin subunit beta  
Inter alpha trypsin heavy chain H4  
Lipopolysaccharide-binding protein  
Thyroxine-binding globulin  









With proteomic analysis of the microvesicle proteome content we detected significant 
changes in haemostatic markers with up-regulation of several coagulation and complement-
related factors during ovarian stimulation. Further, acute phase proteins acting for example in 
response to stress or infection, were altered.  
Among the significantly changed proteins a large number of the up-regulated proteins were 
related to the coagulation and the complement cascade with up-regulated levels of vWF, 
fibrinogen and kininogen-1 that is a precursor of high-molecular-weight kininogen (HMWK) 
and down-regulation of AT and protein S.  
Furthermore, several proteins serving as acute phase reactant proteins were also up-regulated 
indicating a pro-inflammatory state. Levels of the acute phase protein C-reactive protein 
(CRP) was estimated during ovarian stimulation in 28 women undergoing ART with ovarian 
stimulation and showed a high CRP during early ovarian stimulation, measured on day three 
of stimulation, that was associated with treatment failure 154. 
Sex hormone-binding globulin (SHBG) is a main carrier of oestradiol in circulation and was 
up-regulated, which might be expected due to the increased oestrogen level during ovarian 
stimulation. SHBG has been studied as a potential risk marker for VTE during treatment with 
oral contraception. Increased levels of SHBG in COC-users have shown to correlate to 
increased APC-resistance and higher SHBG levels have been found in patients using COC 
that are associated with increased VTE-risk 155 156.  
There are numerous proteomic studies of follicular fluid, oocyte and sperm aimed to predict 
fertilisation, but there is a lack of published studies on the plasma MV proteome during 
ovarian stimulation. We found proteins in our study that could be of interest in both studies of 
fertility and reproduction and regarding the risk of VTE. 
Studying MVs and the MV proteome during ovarian stimulation could increase knowledge 
on what cellular mechanisms and pathways that are activated in response to the oestrogen 
surge. Proteomic studies could also reveal potential biomarkers.  
The multiple comparisons necessitate correction to decrease the significance level and thus 
the number of false positives, but this comes with an increased risk of type 2-errors with 
increased number of false negatives and a risk that there could be hidden potential biomarkers 
among missed detection of significant protein change.  
 
4.3 STUDY III – THE OBSERVATIONAL STUDY 
4.3.1 Results  
Characteristics of the patients in the observational study are presented in table 6 with baseline 
data. The women in the ART groups comprised 3.5 % of the study population. The women in 
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the fresh ET group comprised 25,382 women and 4,946 women comprised the frozen ET 
group. Women in the ART group were approximately six years older than women with 
spontaneous pregnancies. The women in the ART groups also had a higher educational level 
than women with spontaneous pregnancies and a lesser proportion of women with a low 
educational level, i.e. nine years or less.  
 
Table 6. Baseline data of the observational study population. Reprinted with permission from 
the publisher under the Creative Commons CC-BY-NC-ND license 157. 
 
	
	 Fresh	ETa	 Frozen-thawed	ET	 Spontaneous		
	 	 	 	









	 	 	 	
	 Percentage,	%	and	number	(n)	of	women	in	each	group		
Age,	years	 	 	 	
	 	 	 	
		<25	 1.8	(466)	 1.4	(68)	 27.3	(238,417)	
		25-29	 17.7	(4,486)	 14.7	(727)	 38.0	(331,216)	
		30-34	 43.2	(10,955)	 42.1	(2,084)	 25.8	(225,431)	
		≥35	 37.3	(9,475)	 41.8	(2,067)	 8.9	(77,499)	
	 	 	 	
Year	of	delivery	 	 	 	
1992-1996	 11.7	(2,959)	 7.0	(345)	 24.4	(213,078)	
1997-2002	 24.9	(6,308)	 12.4	(615)	 25.0	(218,199)	
2003-2007	 28.4	(7,218)	 30.6	(1,513)	 24.2	(211,552)	
2008-2012	 35.1	(8,897)	 50.0	(2,473)	 26.3	(229,734)	
	 	 	 	
Country	of	birth	 	 	 	
		Sweden	 85.2	(21,615)	 84.1	(4,158)	 82.4	(719,375)	
		Other	 14.8	(3,767)	 15.9	(788)	 17.6	(153,188)	
	 	 	 	
Smoking	status	 	 	 	
		Yes	 4.3	(1,121)	 3.0	(148)	 10.5	(91,153)	
		No	 89.8	(22,726)	 91.4	(4,521)	 84.3	(735,748)	
		Missing	 5.9	(1,535)	 5.6	(277)	 5.2	(45,662)	
	 	 	 	
Body	mass	index,	kg/m2	 	 	 	
		<25	 57.6	(14,619)	 59.8	(2,956)	 61.5	(536,054)	
		25-29	 22.2	(5,633)	 21.6	(1,067)	 18.3	(160,031)	
		≥30	 8.2	(2,082)	 8.1	(402)	 7.2	(62,685)	
		Missing	 12.0	(3,048)	 10.5	(521)	 13.0	(113,793)	
	 	 	 	
Education,	years	 	 	 	
		≤9	 8.8	(2,237)	 8.8	(433)	 17.1	(149,482)	
		10-12	 43.7	(11,085)	 42.7	(2,112)	 46.9	(408,707)	
		>12	 46.9	(11,908)	 48.1	(2,380)	 34.0	(296,720)	
		Missing	 0.6	(152)	 0.4	(21)	 2.0	(17,654)	
	 	 	 	
Single	birth	 87.5	(22,201)	 92.3	(4,566)	 98.9	(862,844)	





The proportion of smokers were higher in women with spontaneous pregnancies.  BMI did 
not to differ markedly between the groups.  
We found an increased incidence of VTE during all pregnancy including nine weeks 
postpartum after fresh ET with 4.7 per 1,000 pregnancies (n=119) as compared to 2.0 per 
1,000 (n=1,760) in spontaneous pregnancies (HR 1.74, 95 % CI 1.43-2.12).  
 
Figure 14. Cumulative incidence of venous thromboembolism after fresh (n=25,382) 
respectively frozen embryo transfer (n=4,946) and after spontaneous conception (n=872,563). 
Reprinted with permission from the publisher under the Creative Commons CC-BY-NC-ND 
license.158. 
 
During the first trimester the incidence of VTE was 1.8 per 1,000 (n=45) as compared to 0.14 
per 1,000 in spontaneous pregnancies (HR 8.96, 95 % CI 6.33-12.67). In table 7 the hazard 
ratios for VTE during pregnancy are presented for the entire pregnancy, including 6 weeks 
postpartum and by trimester.  
Besides the overall VTE events, we also analysed the first incident PE during the first 
trimester in each woman separately and found an incidence of 0.32 per 1,000 (n=8) after 
fresh ET as compared to 0.03 per 1,000 (n=23) in spontaneous pregnancies (HR 8.69, 95 % 
CI 3.83-19.71), figure 15. 
In table 7 the hazard ratios for VTE during the entire pregnancy including postpartum and by 







Figure 15. Cumulative incidence of pulmonary embolism after fresh and frozen embryo 
transfer together (n=30,382) and after spontaneous conception (n=872,563). Reprinted with 




We found an increased incidence of VTE in women undergoing ART with fresh ET as 
compared to women with spontaneous pregnancies. This was most prominent during the first 
trimester with a more than eight-fold increased incidence of VTE as well as PE compared to 
the first trimester in women with spontaneous pregnancies. These results show similarities to 
the findings of Henriksson et al who found an increased incidence in ART-pregnancies as 
compared to spontaneous pregnancies. Thus, the increased incidence during ART 
pregnancies during the first trimester seems to be confined to fresh ET. 
We hypothesise that the reason explaining this finding is the ovarian stimulation with its 
oestrogen surge. The group of women with frozen ET had no increased incidence of VTE 
although the curve of the cumulative incidence could give an expression of a slight increase 
as compared to spontaneous pregnancy. One could speculate on the reason if this is a true 
phenomenon. One reason could be that infertility per se could increase the risk of VTE. 
Another reason could be that the hormones given in a “programmed” cycle during frozen ET 
could have an influence.  
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We found around 20 % PE respectively 80 % DVT in all of the groups, which is similar to 
previous findings in pregnancy.  
Our aim was to study first trimester VTE, but in our material we also found an increased 
incidence of VTE in the postpartum period after fresh ET, which was not found in the 
research group’s previous study 83. We can only speculate why. Other Swedish studies on 
ART pregnancies have found that ART was associated with a higher incidence of caesarean 
section as delivery method and caesarean section is a known risk factor for VTE 159. We 
have, however, not analysed an influence of delivery method in our material. 
A strength of the study is that it is a nationwide study with a large material that included 
almost all women with deliveries in Sweden due to high coverage of the MBR. The study is 
an observational, registry-based study analysed in retrospect. However, the data analysed 
were prospectively collected, which is a strength.  
One limitation of the study is that we lack information on treatment protocols and 
anticoagulant treatment. There could for example be a difference within the group of frozen 
ET between those given a hormone modified “programmed” cycle using exogenous 
hormones including mild stimulation by exogenous oestrogen as compared to a natural cycle.  
Our study could be biased by a so called confounding by indication, which can be seen as a 
type of selection bias where the very reason for the infertility could be the reason for the 
increased adverse outcome, VTE. Thus, women in the ART group could as a whole be more 
prone to VTE, which might explain a part of the difference as compared to spontaneous 
pregnancies. However, the increase in the incidence of VTE in the fresh ET group is of a 
clearly higher magnitude than the previous speculation of a slight increase after frozen ET. 
There is a risk of misclassification regarding the VTE diagnoses. There are studies that     
have shown quite discouraging results regarding VTE diagnoses in the Swedish inpatient 
registry where a positive predictive value (PPV) was 75 % 95, similar to previous Danish 
studies 139 160, but they were not performed specifically on pregnant women. In Denmark a 
study was performed on PPV for diagnose code in pregnancy and postpartum and they found 
a better PPV of 87 %, but which varied within diagnose coding and not all events had 
occurred during pregnancy or postpartum period. The clinical challenge and thus the strive 
for a correct diagnose in pregnancy might in the future result in more accurate diagnose codes 
of VTE.  
A further bias in our study is the immortality time bias by study design and its population, i. 
e. the women included had to survive until child birth and we thus lack information on 
pregnant women who deceased during the pregnancy due to VTE or PE.  
Regarding confounding factors we adjusted for age, BMI, multiple birth, smoking, calendar 
period of diagnosis, educational level as a proxy for socioeconomic status and country of 
birth. There is always the possibility of residual confounding after adjustment and of other 
risk factors not accounted for that affect both exposure and outcome such as OHSS, 
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inflammatory disease, previous cancer, thrombophilia, family history, anticoagulant treatment 
or dosing of exogenous hormones used.  
OHSS might contribute to the observed risk. Rova et al found an incidence of 6-7 % OHSS 
and in the group of OHSS and fresh ET the VTE incidence was profoundly increased as 
compared to women with spontaneous pregnancies. Villani et al in their small cohort of 234 
clinical pregnancies after ART, found 4 % OHSS, where only 30 % were prescribed 
thromboprophylaxis and none in that group had an event. Caveat that this was a very small, 
non-significant material with few events.  
In the ART group you should also consider a possible so called “healthy woman effect” 
which in turn could lead to an underestimation of the risk.  
In our previous study the groups were matched on age and calendar period. In the present 
study we had three groups, making matching a bit more complex since we aimed to compare 
two different exposures, fresh ET and frozen ET, with the same reference group. Thus we 
kept all spontaneous pregnancies after exclusion of the exposed groups and used them as a 
reference group. Yet, we did also perform a matched study analysis, as a sensitivity analysis, 
with the same Cox regression models where each woman in the total ART group (fresh and 
frozen ET) was matched on age with five controls in the group of spontaneous pregnancies 
without a change of the results presented. In figure 16 and figure 17 the graphs after age-
matching are presented.  
 
Figure 16. Age-matched cumulative incidence of venous thromboembolism after fresh 
(n=25,382) respectively frozen embryo transfer (n=4946) and after spontaneous conception 









Figure 17. Age-matched cumulative incidence of pulmonary embolism after fresh and frozen 










• Successful ART with fresh embryo transfer is associated with an increased incidence 
of VTE and PE during pregnancy and postpartum, mostly accounted for by a more 
than eight-fold increase during the first trimester, compared to spontaneous 
pregnancies. 
 
• ART with ovarian stimulation increases the levels of circulating MVs with PMVs and 
EMVs expressing activation markers, indicating a hypercoagulable and 
proinflammatory state during ovarian stimulation. 
 
• Proteomic analysis of MVs revealed alterations in proteins related to coagulation and 
complement activation during ovarian stimulation in ART indicating a 
hypercoagulable and proinflammatory state. We also found alterations of proteins 







6 GENERAL DISCUSSION 
 
The absolute risk of VTE during pregnancy is indeed low. This applies to spontaneous 
pregnancies as well as to pregnancies after assisted reproduction. Despite a low incidence we 
clinicians should do our utmost to prevent this occurrence since VTE can cause severe 
morbidity and even mortality. Risk awareness and assessment is of great importance in order 
to perform ART with minimised risk and preferably without decreasing the chances of 
conceiving a child.  
There might be different reasons for the increased incidence of VTE found in the first 
trimester and postpartum. Ovarian stimulation might be a plausible explanation during the 
first trimester and perhaps the method of delivery, caesarean section, during the post-partum 
period. 
There is a tendency in the VTE curve of frozen ET in figure 14 to be increased as compared 
to spontaneous pregnancies, but this putative increase is not statistically significant. If this 
should be shown to be true in a larger study this might be explained by confounding by 
indication, that infertility might affect the risk of VTE. Furthermore, some women will be 
treated with oestrogen in a “programmed” cycle before frozen ET which could also 
contribute to an increased incidence of VTE. 
The result of our observational study could speak in favour for a freeze-all strategy 
performing embryo transfer when the woman is not hyperstimulated by hormones and with 
the concomitantly increased levels of procoagulant microvesicles and up-regulated 
coagulation factors. 
Another way to handle the risk is to use adequate thromboprophylaxis for pregnant women at 
risk of VTE, with or without ART. This is a way to be able to perform ART without having 
to compromise too much on which method or protocol would be best suited to achieve a 
pregnancy. Women at high risk of VTE before pregnancy should probably start 
thromboprophylaxis already at the start of the ovarian stimulation and if OHSS develops, 
immediately when it is diagnosed. Severe OHSS does indeed carry a major increase in VTE-
risk, but it does not explain the whole risk burden after ART procedures. More studies are 
needed to identify women at risk of hyperstimulation as a cause of VTE. Studies comparing 
different treatment protocols, repeated testing of oestrogen levels and procoagulant and 




7 FUTURE PERSPECTIVES 
 
An increasing number of ART treatments are performed each year in Sweden and ART 
treatment have changed during the years combining an increased possibility of a successful 
pregnancy with a minimized risk of both VTE and obstetric complications.   
Risk assessment and strategies for women with known VTE-risk during pregnancy and ART 
demand a close cooperation between several specialists. Obstetricians and gynaecologists 
together with coagulation specialists have to customise individual treatment to minimise the 
risk. In Sweden such a working group on haemostatic disorders (Hem-Arg) within the 
Swedish Society of Obstetricians and Gynaecologists (SFOG) have developed Swedish 
guidelines and a scoring system for thromboprophylaxis during pregnancy. These 
recommendations even cover ART and when to start thromboprophylaxis depending on risk 
assessment, including risk of OHSS.  
As mentioned, since 2007 the specialised Q-IVF registry has gathered information on almost 
all ART treatments from the fertility clinics in Sweden. With the increasing numbers in the 
registry of both fresh and frozen ETs performed, the power of registry data from Q-IVF to 
perform direct comparisons regarding the VTE-risk of the two methods will increase. The 
addition of biomarkers could also help to identify when to use thromboprophylaxis.  
Our proteomic analysis revealed alterations of proteins related to reproduction. Future studies 
will show whether any of these proteins could be used as biomarkers of a successful ART. 
Women will have to be followed until successful pregnancy and correlation studies could 
identify putative biomarkers. This would also necessitate future larger and repeated 
proteomic studies. Those could contribute to the understanding of the pathways involved and 
identification of biomarkers of successful pregnancy in ART and of risk of diseases such as 
VTE.  
Hopefully future ART treatments will be associated with an increased number of successful 





8 SVENSK SAMMANFATTNING 
 
Venös tromboembolism (VTE) är ett samlingsbegrepp för blodproppar i de djupa venösa 
kärlen och delar av proppar som har lossnat och färdats med cirkulationen, vanligen till 
lungans kärl. Det kallas djup ventrombos (DVT) och lungembolism (LE). Under graviditet 
drabbas 1-2 av 1000 kvinnor av VTE och man har i tidigare studier sett att risken var ännu 
större vid assisterad reproduktionsteknologi (ART), så kallad ”provrörsbefruktning”. Den 
största skillnaden har man sett under den första tredjedelen (trimestern) av graviditeten där 
sju gånger fler kvinnor drabbades av lungemboli under ART-relaterade graviditeter jämfört 
med spontana graviditeter. Användningen av ART ökar kontinuerligt och i Sverige i dag föds 
mer än 4 % av alla barn efter assisterad befruktning.  
Målet med studierna i doktorandprojektet var att öka kunskapen om möjliga mekanismer som 
kan förklara att fler kvinnor drabbas av VTE efter ART jämfört med spontan graviditet. Det 
bör i sin tur öka förståelsen för hur risken för VTE kan minimeras. Eftersom skillnaden var 
som störst i den första trimestern är vår hypotes att det är hormonstegringen vid 
äggstocksstimulering under ART som är orsaken till ökningen.  
Vi skilde därför på ART med färsk embryoåterföring, dvs när graviditeten skett genom 
embryoåterföring direkt efter den fas då kvinnan erhållit behandling med 
äggstocksstimulering, respektive senarelagd embryoåterföring av ett fryst och tinat embryo. 
Vi jämförde hur många som drabbades av VTE och LE i de två grupperna med hur många 
som drabbades vid spontan graviditet. Vi såg att mer än åtta gånger fler drabbades av VTE 
och specifikt av LE i gruppen med färsk embryoåterföring jämfört med spontana graviditeter. 
Skillnaden var som störst under den första trimestern, men en ökning sågs också under hela 
graviditeten och under de första sex veckorna efter förlossningen. I gruppen med frystinad 
embryoåterföring sågs ingen signifikant ökning jämfört med spontana graviditeter. 
Vi studerade också effekten av äggstockstimuleringen på mikrovesiklar och deras 
proteininnehåll. Det gjorde vi genom att undersöka insamlade prover från 31 kvinnor. 
Proverna var tagna före äggstocksstimuleringen när östrogen-nivåerna var nedreglerade och 
under äggstocksstimuleringen när östrogen-nivåerna ökat 10-100-faldigt. Vi såg en ökning av 
mikrovesiklar som indikerade ett prokoagulativt tillstånd med tecken till trombocytaktivering 
som både skulle kunna vara bidragande till en ökad proppbenägenhet och markörer för en 
ökad VTE-risk. Vi studerade även proteininnehållet i mikrovesiklarna och såg en förändring 
av flera proteiner som bidrar både till koagulation och inflammation samt proteiner relaterade 
till reproduktion.  
Sammanfattningsvis är det ovanligt att drabbas av VTE och LE, men man ser en ökad andel 
kvinnor som drabbas under graviditet såväl med som utan assisterad befruktning. Eftersom 
VTE medför en risk för långsiktiga komplikationer och VTE och lungemboli är orsaker 
bakomliggande mödradödlighet är det förstås av yttersta vikt med fortsatta studier för att 
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uppnå en ytterligare ökad förståelse för de bakomliggande mekanismerna för att därigenom 
kunna möjliggöra en minskad risk.  
Det är av stor vikt med fortsatt tvärprofessionell forskning och samarbeten mellan specialister 
inom kvinnors hälsa och reproduktion och specialister verksamma inom området 
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